Login to Your Account

Remynd, Novo Nordisk ink potential $412M diabetes pact

By Cormac Sheridan
Staff Writer

Thursday, December 14, 2017

DUBLIN – Remynd NV could earn up to €350 million (US$412 million) in up-front, research and milestone payments from a licensing deal with Novo Nordisk A/S focused on its preclinical diabetes drug candidate ReS39.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription